The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high ...

Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (NYSE:GMED) from Buy to Neutral.

BTIG analysts have downgraded Globus Medical from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

Two office buildings in Collegeville have sold to Audubon-based Globus Medical for $6.2 million, marking an 81 percent drop ...

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns about its Spine business. The analyst did not assign a price target following ...

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

Nvidia, which is already working with J&J and Medtronic, plans to partner with medtech companies to build platforms for ...

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.

On Tuesday, BTIG analyst Ryan Zimmerman downgraded Globus Medical shares (NYSE:GMED) from Buy to Neutral, citing concerns following the company’s first-quarter results for 2025. According to ...

Globus Medical, Inc. (NYSE:GMED) just released its latest quarterly report and things are not looking great. It wasn't a great result overall - while revenue fell marginally short of analyst ...

Globus Medical reported its financial results for Q1 2025, revealing a miss on both earnings and revenue forecasts. The company posted an earnings per share (EPS) of $0.68, falling short of the ...